Mid-Term Outcomes After Treatment for Antibody-Mediated Rejection by De Novo Donor-Specific HLA Antibody in Renal Transplant Recipients: Does Early Treatment Lead to Better Outcomes?
Sign Up to like & getrecommendations! Published in 2020 at "Transplantation proceedings"
DOI: 10.1016/j.transproceed.2020.06.022
Abstract: BACKGROUND De novo donor-specific HLA antibody (DSA) and antibody-mediated rejection (ABMR) are strongly associated with late allograft loss in renal transplant recipients. However, the impact of therapeutic intervention with the current treatment options for ABMR… read more here.
Keywords: abmr free; treatment; antibody; group ... See more keywords